Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amount
Scandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduced its ownership stake in Scandion Oncology A/S to below 10%. Saniona, together with CEO Nils Brünner and CSO Jan Stenvang initially founded Scandion Oncology A/S in 2017. After the last capital raise in June 2019, Saniona owned approximately 18% of Scandion Oncology. Proceeds from sales of shares will be used to continue Saniona’s advancement of their pipeline, including mid/late-stage clinical trials with Tesomet.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 1, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.
Delårsrapport I 20/21
Periodens resultat: 104,9 (-6,8) MSEK. Ökningen jämfört med föregående år är en engångseffekt av vinst om 117,5 MSEK vid avyttring av aktier i Companion Medical, Inc. Resultat per aktie: 1,5 (-0,1) SEK Kassaflöde från den löpande verksamheten: -14,1 (-6,1) MSEK Likvida medel och kortfristiga p...
Quarterly Report I 20/21
Net result: MSEK 104.9 (-6.8). The increase compared to previous year is a one-off effect of corresponding MSEK 117.5 due to profit from divestment of shares in Companion Medical, Inc. Result per share: SEK 1.5 (-0.1) Cash flow from operating activities: MSEK -14.1 (-6.1) Cash and cash equival...
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to...
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to...